Toronto Dominion Bank cut its stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 11.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 911,371 shares of the company's stock after selling 118,710 shares during the period. Toronto Dominion Bank's holdings in Kenvue were worth $19,457,000 as of its most recent SEC filing.
Other institutional investors have also made changes to their positions in the company. Principle Wealth Partners LLC increased its holdings in shares of Kenvue by 3.7% in the fourth quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company's stock worth $303,000 after acquiring an additional 500 shares in the last quarter. White Pine Capital LLC increased its holdings in shares of Kenvue by 1.0% in the fourth quarter. White Pine Capital LLC now owns 54,572 shares of the company's stock worth $1,165,000 after acquiring an additional 542 shares in the last quarter. Deseret Mutual Benefit Administrators increased its holdings in shares of Kenvue by 29.0% in the fourth quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company's stock worth $54,000 after acquiring an additional 568 shares in the last quarter. SRS Capital Advisors Inc. increased its holdings in shares of Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock worth $30,000 after acquiring an additional 571 shares in the last quarter. Finally, Keystone Financial Group increased its holdings in shares of Kenvue by 4.8% in the fourth quarter. Keystone Financial Group now owns 12,736 shares of the company's stock worth $272,000 after acquiring an additional 578 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.
Kenvue Trading Up 1.2%
KVUE traded up $0.28 during trading on Friday, reaching $23.86. 30,016,864 shares of the stock traded hands, compared to its average volume of 16,346,058. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $45.78 billion, a PE ratio of 45.02, a P/E/G ratio of 2.62 and a beta of 1.02. The stock's 50-day moving average is $23.27 and its 200 day moving average is $22.63. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $25.17.
Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.01. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. The firm had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. During the same quarter in the prior year, the business earned $0.28 earnings per share. The business's quarterly revenue was down 3.9% compared to the same quarter last year. Equities analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.
Kenvue Dividend Announcement
The firm also recently announced a quarterly dividend, which was paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th were issued a $0.205 dividend. The ex-dividend date was Wednesday, May 14th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.44%. Kenvue's dividend payout ratio is presently 149.09%.
Wall Street Analyst Weigh In
Several brokerages have issued reports on KVUE. Barclays increased their price target on Kenvue from $22.00 to $23.00 and gave the stock an "equal weight" rating in a report on Monday, May 12th. Redburn Atlantic started coverage on Kenvue in a report on Thursday, April 10th. They set a "neutral" rating and a $23.50 price objective for the company. UBS Group increased their price objective on Kenvue from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Friday, May 9th. Evercore ISI started coverage on Kenvue in a report on Monday, March 24th. They set an "in-line" rating and a $25.00 price objective for the company. Finally, Piper Sandler increased their price objective on Kenvue from $24.00 to $27.00 and gave the stock an "overweight" rating in a report on Monday, February 24th. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $25.33.
Read Our Latest Stock Report on Kenvue
About Kenvue
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Featured Stories
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
